March 18, 2025 03:38 PM EDT
People
Cell/Gene Tx

Stem cell com­pa­ny bit.bio cuts quar­ter of staff, drops ther­a­peu­tics fo­cus

Ryan Cross

Senior Science Correspondent

The British stem cell com­pa­ny bit.bio has re­duced its work­force by 25%, im­pact­ing most of the ther­a­peu­tics di­vi­sion, founder and board mem­ber Mark Kot­ter con­firmed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Six­teen-year-old dies af­ter re­ceiv­ing Sarep­ta’s Duchenne gene ther­a­py

Up­dat­ed: No­var­tis re­vamps car­dio­vas­cu­lar com­mer­cial strat­e­gy as En­tresto patent cliff looms 

Stoke CEO Ed Kaye to de­part short­ly af­ter ink­ing Bio­gen pact and be­fore its first Phase 3 tri­al

A Japan­ese biotech found­ed by Treg cell dis­cov­er­er moves to the US with $45.8M

Sofinno­va Part­ners lands €165M, backed by big phar­ma, to build ear­ly-stage biotechs in Eu­rope

Em­press Ther­a­peu­tics con­firms lay­offs; Nanobi­otix amends J&J deal terms

A service from the Financial Times